<DOC>
	<DOC>NCT02487693</DOC>
	<brief_summary>The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with ovarian carcinoma.</brief_summary>
	<brief_title>Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma</brief_title>
	<detailed_description>The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with ovarian carcinoma.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
	<criteria>1. patients diagnosed with FIGO stage II ovarian carcinoma; 2. cytoreductive surgery performed and 6 courses of platinumbased chemotherapy completed; 3. medical records maintain comprehensive data on treatment and followup; 4. no history of previous malignancies. 1. neoadjuvant chemotherapy applied; 2. less than 6 courses of chemotherapy or more than 6 courses of chemotherapy completed; 3. medical records maintain incomplete data on treatment or followup; 4. history of previous malignancy.</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>